Form 4: Leap Therapeutics Director Richard Schilsky Acquires 25,000 Stock Options

Director Richard Schilsky reports acquisition of 25,000 stock options in Leap Therapeutics, Inc.

Summary

• Richard Schilsky, a director of Leap Therapeutics, Inc., acquired 25,000 stock options on October 2, 2024.
• The options were granted pursuant to Leap's 2022 Equity Incentive Plan, as amended.
• The exercise price of the options is $2.45.
• The options vest in four quarterly installments starting December 31, 2024, and ending September 30, 2025, contingent upon continued service as a director, consultant, or service provider.
• The options expire on October 2, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally a good sign, but it's a routine transaction and doesn't provide significant new information about the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company, which is generally viewed positively by investors.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates